SCHEMBL2747487

SCHEMBL2747487

O=c1c(O)c[nH]c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 2/20 0.52
ALDH1A1 P00352 3/20 0.50
ATM Q13315 3/20 0.50
MEN1 O00255 2/20 0.50
MAPT P10636 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 2/20 0.50
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CFTR P13569 2/20 0.50
CYP3A4 P08684 1/20 0.50
AHR P35869 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 1/20 0.50
GLA P06280 1/20 0.50
GAA P10253 1/20 0.50
HTT P42858 1/20 0.50
PBRM1 Q86U86 1/20 0.48
GABRA1 P14867 1/20 0.47
GABRB2 P47870 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31739381 1.00 GPR84 (0.52) GPR84ALDH1A1ATMMEN1MAPT
Benzene SCHEMBL4121719 0.98 CFTR (0.53) GPR84ALDH1A1ATMMEN1MAPT
SCHEMBL29567690 0.82 MEN1 (0.58) GPR84ALDH1A1ATMMEN1MAPT
SCHEMBL155191 0.82 MEN1 (0.58) GPR84ALDH1A1ATMMEN1MAPT
Hydrochloric Acid SCHEMBL28628671 0.80 MEN1 (0.56) GPR84ALDH1A1ATMMEN1MAPT
SCHEMBL28624457 0.80 MEN1 (0.56) GPR84ALDH1A1ATMMEN1MAPT
SCHEMBL10550137 0.80 MEN1 (0.56) GPR84ALDH1A1ATMMEN1MAPT
Methane SCHEMBL5065725 0.80 MEN1 (0.56) GPR84ALDH1A1ATMMEN1MAPT
SCHEMBL27702719 0.80 MEN1 (0.56) GPR84ALDH1A1ATMMEN1MAPT
Water SCHEMBL27616945 0.80 MEN1 (0.56) GPR84ALDH1A1ATMMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866842-A2 A COMPOSITION, METHOD OF AUTHENTICATING, METHODS OF MAKING AUTHENTICATABLE COMPOSITIONS, AUTHENTICATABLE ARTICLES MADE THERE FROM General Electric Company (US) 2007-12-19 EP claimed
WO-2006065561-A2 A COMPOSITION, METHOD OF AUTHENTICATING, METHODS OF MAKING AUTHENTICATABLE COMPOSITIONS, AUTHENTICATABLE ARTICLES MADE THERE FROM GENERAL ELECTRIC COMPANY (US) 2006-06-22 WO claimed
US-20060131761-A1 Composition, method of authenticating, methods of making authenticatable compositions, authenticatable articles made there from SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2006-06-22 US claimed
US-11753222-B2 Powdered pouch and method of making same MONOSOL, LLC (US) 2023-09-12 US disclosed
EP-2825624-B2 WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND METHOD OF MAKING SAME MONOSOL LLC (US) 2022-07-27 EP disclosed
EP-2838811-B2 POWDERED POUCH AND METHOD OF MAKING SAME MONOSOL LLC (US) 2022-06-29 EP disclosed
EP-2763539-B1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LTD (GB) 2017-02-08 EP disclosed
US-9340556-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2016-05-17 US disclosed
CN-101972492-B Medical product for curing body channel narrow and preventing dangerous restenosis HEMOTEQ AG 2014-12-10 CN disclosed
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-09-04 US disclosed
CN-101687066-B Medical product for treating stenosis of body passageways and preventing dangerous restenosis HEMOTEQ AG 2013-09-11 CN disclosed
EP-1642109-A4 METHODS FOR CONDUCTING ASSAYS FOR ENZYME ACTIVITY ON PROTEIN MICROARRAYS PROTOMETRIX INC (US) 2007-09-05 EP disclosed
US-20060131761-A1 Composition, method of authenticating, methods of making authenticatable compositions, authenticatable articles made there from SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2006-06-22 US disclosed
WO-2006065561-A2 A COMPOSITION, METHOD OF AUTHENTICATING, METHODS OF MAKING AUTHENTICATABLE COMPOSITIONS, AUTHENTICATABLE ARTICLES MADE THERE FROM GENERAL ELECTRIC COMPANY (US) 2006-06-22 WO disclosed
EP-1642109-A2 METHODS FOR CONDUCTING ASSAYS FOR ENZYME ACTIVITY ON PROTEIN MICROARRAYS Protometrix, Inc. (US) 2006-04-05 EP disclosed
US-6919335-B2 Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection BRISTOL-MYERS SQUIBB CO. (US) 2005-07-19 US disclosed
WO-2005003721-A2 ENZYME ACTIVITY ASSAYS ON PROTEIN MICROARRAYS PROTOMETRIX, INC. (US) 2005-01-13 WO disclosed
EP-1276739-A2 HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME Bristol-Myers Squibb Company (US) 2003-01-22 EP disclosed
US-20020040022-A1 Heterocycles that are inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY 2002-04-04 US disclosed
WO-2001081340-A2 HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040022-A1 Heterocycles that are inhibitors of IMPDH enzyme XDH, IMPDH1, IMPDH2 GPR84 3934/4885ALDH1A1 155/4885ATM 2467/4885
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS MRPL21, PEPD, ABCB11 GPR84 4339/4885ALDH1A1 3841/4885ATM 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.